enGene initiates $20 million financing to advance lead product

Closely held enGene of Vancouver is working on a financing of up to $20 million with venture capital funds to conduct the first two phases of human clinical trials of its intestinal immunotherapy platform to treat ulcerative colitis, a major subtype of Inflammatory Bowel Disease (IBD). “We have built significant momentum for the financing in [...]

Cellceutix’s potential breakthrough in cancer research

Cellceutix (OTCBB:CTIX) of Beverly, Mass. believes it has found the Holy Grail in cancer research: a compound that activates a tumor suppressor protein known as p53, long regarded as possibly holding the key to future cancer therapies. “Our Kevetrin drug reactivates p53 to its normal function of dictating whether to fix the cell or kill [...]

In conversation with Eric Adams

As CEO of privately held enGene, Eric Adams likes to say that the promise of DNA-based medicines, or gene therapy, is a few steps closer to being unlocked because of the Vancouver-based company. That’s because enGene has developed a technology that delivers DNA or small interfering RNA (siRNA) nucleotides to mucosal tissues such as the [...]

Medical Lab division to drive Warnex

After obtaining rights to a colorectal cancer blood screening test in May, Warnex (TSX:WNX) is looking for additional products to license into its Medical Laboratories division as it seeks to become the “unique provider” of specialized diagnostic tests in Canada. “Our other divisions are coming out of the recession okay, and we getting busy.  But [...]